Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
XERS

XERS - Xeris Pharmaceuticals Inc Stock Price, Fair Value and News

$7.14-0.37 (-4.93%)
Market Closed

56/100

XERS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

56/100

XERS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$7.82

Target 3M

$7.53

Target 6M

$7.63

XERS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

XERS Price Action

Last 7 days

-6.3%

Last 30 days

-3.9%

Last 90 days

-26.5%

Trailing 12 Months

102.3%

XERS RSI Chart

XERS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

XERS Valuation

Market Cap

1.2B

Price/Earnings (Trailing)

-75.75

Price/Sales (Trailing)

4.45

Price/Free Cashflow

112.21

XERS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$7.82

Target 3M

$7.53

Target 6M

$7.63

XERS Fundamentals

XERS Revenue

Revenue (TTM)

266.1M

Rev. Growth (Yr)

37.06%

Rev. Growth (Qtr)

3.97%

XERS Earnings

Earnings (TTM)

-15.6M

Earnings Growth (Yr)

103.95%

Earnings Growth (Qtr)

132.21%

XERS Profitability

Return on Equity

1.8K%

Return on Assets

-4.22%

Free Cashflow Yield

0.89%

XERS Investor Care

Shares Dilution (1Y)

11.30%

Diluted EPS (TTM)

-0.09

XERS Alerts

  • 3 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025222.6M246.0M266.1M0
2024171.4M181.4M187.4M203.1M
2023121.4M134.1M152.7M163.9M
202263.5M79.9M98.5M110.2M
202127.7M35.0M42.3M49.6M
202000020.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About Xeris Pharmaceuticals Inc

XERS
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company markets Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
 CEO
 WEBSITExerispharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES355

Xeris Pharmaceuticals Inc Frequently Asked Questions

XERS is the stock ticker symbol of Xeris Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Xeris Pharmaceuticals Inc is 1.18 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check XERS's fair value in chart for subscribers.

The fair value guage provides a quick view whether XERS is over valued or under valued. Whether Xeris Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Xeris Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for XERS.

As of Wed Jan 28 2026, XERS's PE ratio (Price to Earnings) is -75.75 and Price to Sales (PS) ratio is 4.45. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. XERS PE ratio will change depending on the future growth rate expectations of investors.